Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 21 microgram/actuation - inhalation, pressurised - excipient ingredients: ethanol absolute; citric acid; purified water; norflurane - atrovent metered aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with asthma and chronic obstructive pulmonary disease (copd).

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - ipratropium bromide - respirator solution - ipratropium bromide 0.25 mg/ml - ipratropium bromide - ipratropium bromide - for the relief of symptoms of reversible bronchospasm associated with asthma, chronic bronchitis and emphysema . aerovent respirator solution is of particular benefit in relieving acute bronchospasm when used concomitantly with inhaled beta agonists.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - ipratropium bromide - respirator solution - ipratropium bromide 0.25 mg/ml - ipratropium bromide - for the relief of symptoms of reversible bronchospasm associated with asthma, chronic bronchitis and emphysema . aerovent respirator solution is of particular benefit in relieving acute bronchospasm when used concomitantly with inhaled beta agonists.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 522 microgram/ml (equivalent: ipratropium bromide, qty 500 microgram/ml) - inhalation, conventional - excipient ingredients: sodium chloride; hydrochloric acid; purified water - moderate asthmatic attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery, use during assisted ventilation with a respirator. administration of atrovent via a nebuliser is intended for those patients who cannot use a metered dose aerosol.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 0.261 mg/ml (equivalent: ipratropium bromide, qty 0.25 mg/ml) - inhalation, conventional - excipient ingredients: purified water; benzalkonium chloride; sodium chloride; hydrochloric acid; disodium edetate - moderate asthmatic attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery, use during assisted ventilation with a respirator. administration of atrovent via a nebuliser is intended for those patients who cannot use a metered dose aerosol.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 261 microgram/ml (equivalent: ipratropium bromide, qty 250 microgram/ml) - inhalation, conventional - excipient ingredients: purified water; sodium chloride; hydrochloric acid - moderate asthmatic attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery, use during assisted ventilation with a respirator. administration of atrovent via a nebuliser is intended for those patients who cannot use a metered dose aerosol.

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone acetate 1 mg - aurovela 24 fe is indicated for use by women to prevent pregnancy [see clinical studies (14)] . the efficacy of aurovela 24 fe in women with a body mass index (bmi) of greater than 35 kg/m2 has not been evaluated. aurovela 24 fe is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)] have coronary artery disease [see warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precau

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone acetate 1 mg - aurovela 1/20 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. - oral contraceptives are contraindicated in women who currently have the following conditions: - thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders - cerebral vascular or coronary artery disease - current diagnosis of, or history of, breast cancer, which may be hormone sensitive - carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia - undiagnosed abnormal genital bleeding - cholestatic jaundice of pregnancy

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone acetate 1.5 mg - aurovela 1.5/30 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates.  - oral contraceptives are contraindicated in women who currently have the following conditions: - thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders - cerebral vascular or coronary artery disease - current diagnosis of, or history of, breast cancer, which may be hormone sensitive - carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia - undiagnosed abnormal genital bleeding - cholestatic jaundice of pregnancy o

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone acetate 1.5 mg - aurovela fe 1.5/30 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. - oral contraceptives are contraindicated in women who currently have the following conditions: - thrombophlebitis or thromboembolic disorders - a past history of deep vein thrombophlebitis or thromboembolic disorders - cerebral vascular or coronary artery disease - current diagnosis of, or history of, breast cancer, which may be hormone sensitive - carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia - undiagnosed abnormal genital bleeding - cholestatic jaundice of preg